Neoss® is a partner you can trust. We are dedicated to conducting long-term clinical follow-ups on our entire product portfolio.
Internationally-recognized researchers and clinicians have gathered supporting data on more than 2350 implants in over 830 patients, with a follow-up of one to six years. This data is then published in peer-reviewed journals.
Based on the clinical results, the Neoss implant system can be considered one of the most advanced and clinically successful systems available today.
Stable long term marginal bone levels
Without exception, all published clinical data on Neoss - regardless of indication - show only minor initial bone loss and stable values thereafter. The maximum mean bone loss reported in any paper is 0.8 mm, demonstrating the consistent clinical performance of Neoss implants.
The stability of marginal bone level is also apparent when looking at individual cases. In the published literature on Neoss implants, there are virtually no cases of excessive bone loss (>3 mm), which is a prerequisite and dominating factor for good resistance to peri-implantitis.
Challenging indications and loading protocols
Long-term clinical studies further support the clinical benefits of Neoss implants, with high success rates in challenging indications such as placement in augmented bone, extraction sites, irradiated tumor patients, or in conjunction with sinus lift procedures.
High primary stability can be predictably achieved with Neoss ProActive® Implants (ISQ > 70). This is also the case in augmented bone. Additional stability in soft bone can be achieved using the Neoss ProActive Tapered implant.
ProActive surface – improved clinical outcome for different loading protocols
The superhydrophilic Neoss ProActive surface demonstrates improved success rates compared to a blasted surface in high risk indications such as guided bone regeneration, immediate loading, and compromised bone.